# BPC-157 TB-500: The Wolverine Blend, Read as an Evidence Ledger
> BPC-157 TB-500 is the two-peptide Wolverine blend — two distinct synthetic peptides with separate mechanisms and no controlled combination trial. A cited evidence ledger of the record.
Two synthetic peptides, two separate mechanisms, one honest gap. A barely-there ledger of what the single-compound literature establishes and where the blend's claims stop — every quantitative claim cited.
## BPC-157 and TB-500: The Two Peptides in the Wolverine Blend
BPC-157 TB-500 is the research-community name for a two-peptide pairing, not a single chemical entity. The blend has no molecular weight, no CAS number, and no approved indication. It is two distinct synthetic peptides put in one vial. BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV, ~1419.5 Da, derived from a protein found in human gastric juice. TB-500 is a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, ~889 Da, corresponding to residues 17-23 — the actin-binding motif — of the 43-residue protein Thymosin Beta-4.
The two are paired on a theoretical basis: BPC-157 supplies a local angiogenic and cytoprotective signal, while TB-500 supplies a cytoskeletal cell-migration signal. They act through complementary but largely non-overlapping pathways. That is the whole case for the combination — two separately characterized mechanisms, not a tested unit. No controlled trial has ever defined a synergistic dose, ratio, or endpoint for the two given together [6].
This site reads that record as a ledger. What the single-compound literature establishes sits in one tier; what the blend itself has never demonstrated sits one tier down, marked plainly. The evidence is overwhelmingly preclinical and single-compound, and the [BPC-157 TB-500 benefits](/recovery-research) described in forums outrun what the published animal studies actually measured. The [BPC-157 TB-500 dosage in the literature](/dosage) is single-compound and per-body-weight, with no validated blend dose, and the [FDA 503A compounding status](/legal-status) places both components in Category 2 — restricted pending review.
## What the Wolverine blend is — and is not
### What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair 'stack'. It is not a single chemical entity and not an approved product. The name borrows from the fictional character's regenerative reputation; the underlying peptides are two synthetic research compounds with separately studied mechanisms.
### What is BPC-157 and TB-500?
BPC-157 is a pentadecapeptide (GEPPPGKPADDAGLV) reported to be pro-angiogenic via a VEGFR2-Akt-eNOS pathway [2]. TB-500 is the N-acetylated heptapeptide Ac-LKKTETQ, the actin-binding fragment of Thymosin Beta-4 [3][5]. They are two distinct synthetic peptides, combined in the blend.
### What the 'Wolverine Peptide Stack' Refers To
The 'Wolverine peptide stack' is forum shorthand for the BPC-157 plus TB-500 pairing, named for the comic character's rapid healing. It refers to a research-community blend, not a defined product or a studied unit. The name is marketing and community vocabulary; the science underneath is two single-compound literatures.
### The BPC-157 TB-500 Stack ('Wolverine')
The BPC-157 TB-500 stack circulates on forums as a tendon-and-soft-tissue protocol, typically as fixed-ratio vials. No controlled human trial has tested that stack [6][7]. Treating a community 'stack' name as if it were a validated regimen is the central error this ledger is built to avoid.
## Two mechanisms, read separately
### How does BPC-157 work compared to TB-500?
BPC-157 up-regulates VEGFR2 with downstream Akt-eNOS angiogenic signaling, modulates nitric oxide, and sensitizes tendon fibroblasts to growth hormone [2]. TB-500 works through 1:1 sequestration of monomeric G-actin and cytoskeletal remodeling [3]. They act through complementary but largely non-overlapping pathways — the basis, and the limit, of the synergy claim.
### How does TB-500 work?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it by capping both ends, preventing polymerization. X-ray crystallography of a Thymosin Beta-4-actin complex established this structural basis [3]; the regulated actin pool underlies cell migration and re-epithelialization. This is [how TB-500 sequesters actin](/#how-tb500-works) — a buffering mechanism, not a growth factor.
### What does TB-500 stand for and how does it relate to Thymosin Beta-4?
TB-500 is the synthetic N-acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17-23 (the actin-binding motif) of Thymosin Beta-4, a 43-amino-acid intracellular actin-sequestering protein [3][4][5]. Most efficacy data attributed to 'TB-500' were actually generated with full-length Thymosin Beta-4, not the 7-mer — a caveat that doubles inside the blend.
### What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid pentadecapeptide acting mainly through VEGFR2-Akt-eNOS angiogenesis, nitric-oxide modulation, and growth-hormone-receptor sensitization [2]. TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting through 1:1 G-actin sequestration that regulates cell migration [3]. Different sizes, different proposed pathways.
### BPC 157 TB 500: Spacing and Naming Variants
BPC 157 TB 500, BPC-157 TB-500, BPC157 TB500, and 'the Wolverine blend' all name the same two-peptide pairing; the spacing and hyphenation vary, the compounds do not. Use of the unspaced or hyphen-free form in forums and product listings does not denote a different formulation.
---
A barely-there evidence ledger of the BPC-157 and TB-500 record — the few single-compound findings that hold set in one tier, the blend-level and access gaps left one tier down and in plain sight, with no clinic behind the page and nothing here dispensed.